Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97784457

Filing Date: 02/07/2023

To the Commissioner for Trademarks:

MARK: KITE (Standard Characters, see mark)
The literal element of the mark consists of KITE. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Kite Pharma, Inc., a corporation of Delaware, having an address of
      2400 Broadway
      Santa Monica, California 90404
      United States
      650-522-5575(fax)
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 036:  Financial administration of patient reimbursement programs; financial administration of medication reimbursement programs and services

In International Class 036, the mark was first used by the applicant or the applicant's related company or licensee or predecessor in interest at least as early as 01/01/2020, and first used in commerce at least as early as 01/01/2020, and is now in use in such commerce. The applicant is submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in the class of listed goods/services, consisting of a(n) Screenshot from Applicant's website www.kitekonnect.com downloaded on February 6, 2023 displaying the mark in use.

Original PDF file:
SPE0-19215623611-20230206 163742515131_._Kite_Class _36.pdf
Converted PDF file(s) (2 pages)
Specimen File1
Specimen File2
Webpage URL: www.kitekonnect.com
Webpage Date of Access: 02/06/2023

International Class 040:  Custom manufacturing of biological tissue, blood, and cells; custom manufacturing of pharmaceutical preparations for immunotherapy

In International Class 040, the mark was first used by the applicant or the applicant's related company or licensee or predecessor in interest at least as early as 06/30/2020, and first used in commerce at least as early as 06/30/2020, and is now in use in such commerce. The applicant is submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in the class of listed goods/services, consisting of a(n) marketing materials and screenshot from Applicant's websites http://www.yescartahospitalbillingcoding.com and http://www.yescarta.com/lbcl/what-is-car-t-cell-therapy downloaded on February 6, 2023 displaying the mark in use.

Original PDF file:
SPE0-1-19215623611-202302 06163742515131_._Kite_Cla ss_40.pdf
Converted PDF file(s) (2 pages)
Specimen File1
Specimen File2
Original PDF file:
SPE0-19215623611-20230206 163742515131_._Kite40.2.pdf
Converted PDF file(s) (26 pages)
Specimen File1
Specimen File2
Specimen File3
Specimen File4
Specimen File5
Specimen File6
Specimen File7
Specimen File8
Specimen File9
Specimen File10
Specimen File11
Specimen File12
Specimen File13
Specimen File14
Specimen File15
Specimen File16
Specimen File17
Specimen File18
Specimen File19
Specimen File20
Specimen File21
Specimen File22
Specimen File23
Specimen File24
Specimen File25
Specimen File26
Webpage URL: http://www.yescarta.com/lbcl/what-is-car-t-cell-therapy
Webpage Date of Access: 02/06/2023
Webpage URL: http://www.yescartahospitalbillingcoding.com
Webpage Date of Access: 02/06/2023

International Class 044:  Providing medical information; providing a web site featuring medical information; providing medical information, consultancy and advisory services; collection and preservation of biological tissue, blood and cells

In International Class 044, the mark was first used by the applicant or the applicant's related company or licensee or predecessor in interest at least as early as 06/25/2021, and first used in commerce at least as early as 06/25/2021, and is now in use in such commerce. The applicant is submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in the class of listed goods/services, consisting of a(n) screenshot form Applicant's website www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/adverse-events downloaded on February 6, 2023 displaying the mark in use.

Original PDF file:
SPE0-19215623611-20230206 163742515131_._Kite_Class __44.pdf
Converted PDF file(s) (2 pages)
Specimen File1
Specimen File2
Webpage URL: www.tecartushcp.com/car-t-cell-therapy/mantle-cell-lymphoma/adverse-events
Webpage Date of Access: 02/06/2023

International Class 045:  Providing patient advocate services in the field of the treatment of diseases and disorders

In International Class 045, the mark was first used by the applicant or the applicant's related company or licensee or predecessor in interest at least as early as 01/01/2020, and first used in commerce at least as early as 01/01/2020, and is now in use in such commerce. The applicant is submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in the class of listed goods/services, consisting of a(n) screenshot from Applicant's website www.kitekonnect.com downloaded on February 6, 2023 displaying the mark in use.

Original PDF file:
SPE0-19215623611-20230206 163742515131_._Kite_Class __36.pdf
Converted PDF file(s) (2 pages)
Specimen File1
Specimen File2
Webpage URL: www.kitekonnect.com
Webpage Date of Access: 02/06/2023



For informational purposes only, applicant's website address is: www.kitepharma.com

The owner's/holder's proposed attorney information: Cynthia Smuzynska. Other appointed attorneys are Gretchen R. Stroud; Jack Wessel; Lori Mayall; Shelley Lai; Peter Colosi. Cynthia Smuzynska of Gilead Sciences, Inc., is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      333 Lakeside Drive
      Foster City, California 94404
      United States
      650-522-5563(phone)
      650-522-5575(fax)
      trademarks@gilead.com
The docket/reference number is TBD.
Cynthia Smuzynska submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Cynthia Smuzynska

PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gilead.com        SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): TMTeam@gilead.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $1400 has been submitted with the application, representing payment for 4 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /cynthia smuzynska/   Date: 02/07/2023
Signatory's Name: Cynthia Smuzynska
Signatory's Position: Senior Counsel, IP
Signatory's Phone Number: 650-522-5563
Signature method: Sent to third party for signature
Payment Sale Number: 97784457
Payment Accounting Date: 02/07/2023

Serial Number: 97784457
Internet Transmission Date: Tue Feb 07 16:05:53 ET 2023
TEAS Stamp: USPTO/BAS-XXX.XXX.XXX.XX-202302071605536
36812-97784457-86027e81d87d847b834d68c83
ac1a93f88fc73d7969cd8856dbdfa32461e3ff48
-DA-05532768-20230206191148605180